Hidejiro Torigoe

681 citations

28 papers · 450 indexed · h-index 13

Co-authors: Shinichi Toyooka Junichi Soh Shuta Tomida Hiromasa Yamamoto Kazuhiko Shien Hiroki Sato Kei Namba Takahiro Yoshioka
Topics: Lung Cancer Treatments and Mutations (13 papers)HER2/EGFR in Cancer Research (7 papers)Lung Cancer Diagnosis and Treatment (5 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: PLoS ONE Cancer Research Scientific Reports
Partner nations: Japan United States

In The Last Decade

Hidejiro Torigoe

24 papers receiving 449 citations

Peers

Countries citing papers authored by Hidejiro Torigoe

Since Specialization

Citations

This map shows the geographic impact of Hidejiro Torigoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hidejiro Torigoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hidejiro Torigoe more than expected).

Fields of papers citing papers by Hidejiro Torigoe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hidejiro Torigoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hidejiro Torigoe. The network helps show where Hidejiro Torigoe may publish in the future.

Co-authorship network of co-authors of Hidejiro Torigoe

This figure shows the co-authorship network connecting the top 25 collaborators of Hidejiro Torigoe. A scholar is included among the top collaborators of Hidejiro Torigoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hidejiro Torigoe. Hidejiro Torigoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer 2019 ·Anticancer Research ·Eisuke Kurihara,Kazuhiko Shien,Hidejiro Torigoe,(unknown),Yuta Takahashi,(unknown),Takahiro Yoshioka,Kei Namba,Hiroki Sato,Ken Suzawa,Hiromasa Yamamoto,Junichi Soh,Mikio Okazaki,Tadahiko Shien,Shuta Tomida,Shinichi Toyooka	8
2	Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells 2019 ·Cancer Science ·Takahiro Yoshioka,Kazuhiko Shien,(unknown),Yuta Takahashi,Eisuke Kurihara,(unknown),Kei Namba,Hidejiro Torigoe,Hiroki Sato,Shuta Tomida,Hiromasa Yamamoto,Junichi Soh,Toshiyoshi Fujiwara,Shinichi Toyooka	30
3	Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma 2019 ·BMC Cancer ·Kei Namba,Shuta Tomida,Takehiro Matsubara,Yuta Takahashi,Eisuke Kurihara,(unknown),Takahiro Yoshioka,(unknown),Hidejiro Torigoe,Hiroki Sato,Kazuhiko Shien,Hiromasa Yamamoto,Junichi Soh,Kazunori Tsukuda,Shinichi Toyooka	1
4	Migration of a hookwire used as a video-assisted thoracoscopic surgery marker into the splenic artery 2019 ·General Thoracic and Cardiovascular Surgery ·Hidejiro Torigoe,Yutaka Hirano,Yukio Ando,(unknown)	5
5	Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma 2019 ·International Journal of Oncology ·Hiroki Sato,Junichi Soh,Keisuke Aoe,Nobukazu Fujimoto,Shin Tanaka,Kei Namba,Hidejiro Torigoe,Kazuhiko Shien,Hiromasa Yamamoto,Shuta Tomida,Hiroyuki Tao,Kazunori Okabe,Takumi Kishimoto,Shinichi Toyooka	19
6	Growth Process of Metastatic Lung Cancer with a Thin-walled Cavity 2019 ·Haigan ·Hidejiro Torigoe,Yutaka Hirano,(unknown)	0
7	Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells 2018 ·Molecular Cancer Research ·Kei Namba,Kazuhiko Shien,Yuta Takahashi,Hidejiro Torigoe,Hiroki Sato,Takahiro Yoshioka,(unknown),Eisuke Kurihara,(unknown),Hiromasa Yamamoto,Junichi Soh,Shuta Tomida,Shinichi Toyooka	71
8	Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations 2018 ·Cancer Science ·Hidejiro Torigoe,Kazuhiko Shien,(unknown),Takahiro Yoshioka,Kei Namba,Hiroki Sato,Ken Suzawa,Hiromasa Yamamoto,Junichi Soh,Masakiyo Sakaguchi,Shuta Tomida,Kazunori Tsukuda,Shinichiro Miyoshi,Shinichi Toyooka	20
9	Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma 2018 ·Oncogenesis ·Hiroki Sato,Masakiyo Sakaguchi,Hiromasa Yamamoto,Shuta Tomida,Keisuke Aoe,Kazuhiko Shien,Takahiro Yoshioka,Kei Namba,Hidejiro Torigoe,Junichi Soh,Kazunori Tsukuda,Hiroyuki Tao,Kazunori Okabe,Shinichiro Miyoshi,Harvey I. Pass,Shinichi Toyooka	9
10	Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer 2018 ·Cancer Science ·Takahiro Yoshioka,Kazuhiko Shien,Kei Namba,Hidejiro Torigoe,Hiroki Sato,Shuta Tomida,Hiromasa Yamamoto,Hiroaki Asano,Junichi Soh,Kazunori Tsukuda,Takeshi Nagasaka,Toshiyoshi Fujiwara,Shinichi Toyooka	35
11	Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer 2017 ·PLoS ONE ·(unknown),Hiromasa Yamamoto,Hirotaka Kanzaki,Ken Suzawa,Takahiro Yoshioka,Shuta Tomida,Xiaojiang Cui,Ramachandran Murali,Kei Namba,Hiroki Sato,Hidejiro Torigoe,Mototsugu Watanabe,Kazuhiko Shien,Junichi Soh,Hiroaki Asano,Kazunori Tsukuda,Yoshihisa Kitamura,Shinichiro Miyoshi,Toshiaki Sendo,Shinichi Toyooka	29
12	P3.02b-121 Targeting miR-200c/LIN28B Axis in Acquired EGFR-TKI Resistance Non-Small Cell Lung Cancer Cells Harboring EMT Features 2017 ·Journal of Thoracic Oncology ·Kazuhiko Shien,Hiroki Sato,Ken Suzawa,Shuta Tomida,Shinsuke Hashida,Hiromasa Yamamoto,Junichi Soh,Hidejiro Torigoe,Kei Namba,Mototsugu Watanabe,Hiroaki Asano,Kazunori Tsukuda,Shinichiro Miyoshi,Shinichi Toyooka	1
13	Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer 2017 ·Journal of Thoracic Disease ·Hidejiro Torigoe,Junichi Soh,Shuta Tomida,Kei Namba,Hiroki Sato,Kuniaki Katsui,Katsuyuki Hotta,Kazuhiko Shien,Hiromasa Yamamoto,Masaomi Yamane,Susumu Kanazawa,Katsuyuki Kiura,Shinichiro Miyoshi,Shinichi Toyooka	4
14	Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features 2017 ·Scientific Reports ·Hiroki Sato,Kazuhiko Shien,Shuta Tomida,(unknown),Ken Suzawa,Shinsuke Hashida,Hidejiro Torigoe,Mototsugu Watanabe,Hiromasa Yamamoto,Junichi Soh,Hiroaki Asano,Kazunori Tsukuda,Shinichiro Miyoshi,Shinichi Toyooka	48
15	Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer 2017 ·Oncology Letters ·Haiyang Chen,Kazuhiko Shien,Ken Suzawa,Kazunori Tsukuda,Shuta Tomida,Hiroki Sato,Hidejiro Torigoe,Mototsugu Watanabe,Kei Namba,Hiromasa Yamamoto,Junichi Soh,Hiroaki Asano,Shinichiro Miyoshi,Shinichi Toyooka	22
16	Abstract 3156: Multiple acquired resistance mechanisms against third generation EGFR-TKI osimeritinib in non-smal cell lung cancer cells 2017 ·Cancer Research ·Kei Namba,Kazuhiko Shien,Takahiro Yoshioka,Hidejiro Torigoe,Hiroki Sato,Hiromasa Yamamoto,Junichi Soh,Kazunori Tsukuda,Shinichi Toyooka	1
17	Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway 2016 ·Scientific Reports ·Tomoaki Ohtsuka,Masakiyo Sakaguchi,Hiromasa Yamamoto,Shuta Tomida,Katsuyoshi Takata,Kazuhiko Shien,Shinsuke Hashida,Tomoko Miyata‐Takata,Mototsugu Watanabe,Ken Suzawa,Junichi Soh,Youyi Chen,Hiroki Sato,Kei Namba,Hidejiro Torigoe,Kazunori Tsukuda,Tadashi Yoshino,Shinichiro Miyoshi,Shinichi Toyooka	22
18	Abstract 4392: Yes1 is the key molecule for the resistance to trastuzumab in breast cancer, and dasatinib overcomes the resistance 2016 ·Cancer Research ·Hiromasa Yamamoto,(unknown),Hirotaka Kanzaki,Ken Suzawa,Kei Namba,Hiroki Sato,Hidejiro Torigoe,Mototsugu Watanabe,Yuho Maki,Junichi Soh,Hiroaki Asano,Kazunori Tsukuda,Shinichiro Miyoshi,Yoshihisa Kitamura,Toshiaki Sendo,Shinichi Toyooka	2
19	[Cross-sectoral Approach of a Perioperative Management Center for General Thoracic Surgery]. 2016 ·PubMed ·Atsushi Shimoda,Junichi Soh,(unknown),(unknown),(unknown),(unknown),Hidejiro Torigoe,Yuho Maki,Seiichiro Sugimoto,Masaomi Yamane,Shinichi Toyooka,Takahiro Oto,Shinichiro Miyoshi	6
20	Induction S-1+Concurrent Radiotherapy Followed by Surgical Resection of Locally Advanced Non-small-cell Lung Cancer in an Elderly Patient. 2016 ·PubMed ·Hidejiro Torigoe,Shinichi Toyooka,Kuniaki Katsui,Junichi Soh,Yuho Maki,Katsuyuki Kiura,Shinichiro Miyoshi	1

About Hidejiro Torigoe

Hidejiro Torigoe is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 28 papers that have together received 450 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (7 papers) and Lung Cancer Diagnosis and Treatment (5 papers). The work is most often cited by research in Oncology (216 citations), Cancer Research (108 citations) and Pulmonary and Respiratory Medicine (186 citations). Hidejiro Torigoe has collaborated with scholars based in Japan and United States. Frequent co-authors include Shinichi Toyooka, Junichi Soh, Shuta Tomida, Hiromasa Yamamoto, Kazuhiko Shien, Hiroki Sato, Kei Namba, Takahiro Yoshioka, Eisuke Kurihara and Ken Suzawa. Their work appears in journals such as PLoS ONE, Cancer Research and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact